Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 1721 • ACR Convergence 2022
Protective Effects of the Natural Antioxidant Taxifolin in Models of Lupus and Antiphospholipid Syndrome
Christine Rysenga¹, Linda May-Zhang², Miela Zahavi³, Jason S Knight⁴ and Ramadan Ali¹, ¹University of Michigan, Ann Arbor, MI, ²Blue California, Rancho Santa Margarita, CA, ³Universtiy of Michigan, Ann Arbor, MI, ⁴University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: Taxifolin, also known as dihydroquercetin, is a bioactive flavonoid commonly found in apples, onions, French maritime bark, and milk thistle. Given its potent anti-inflammatory…
Abstract Number: 0686 • ACR Convergence 2022
Anti-β2GP1/HLA-DR Antibody Is Associated with Arterial Thrombosis in Female Patients with Connective Tissue Diseases: A Cross-Sectional Study in Japan
Katsuhiko Yoneda¹, Yo Ueda¹, Kenji Tanimura², Hirotaka Yamada¹, Takaichi Okano³, Keisuke Nishimura¹, Hisashi Arase⁴, Hideto Yamada⁵ and Jun Saegusa¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Obstetrics and Gynecology, Kobe University Hospital, Kobe, Japan, ³Kobe University Hospital, Kobe, Japan, ⁴Department of Immunochemistry, Research Institute for Microbial Disease, Osaka University, Suita, Japan, ⁵Department of Obstetrics and Gynecology, Kobe University Hospital / Center for Recurrent Pregnancy Loss, Teine Keijinkai Hospital, Sapporo, Japan
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and/or pregnancy complications. Recently, β2-glycoprotein I (β2GPI) complexed with HLA class II molecules (β2GPI/HLA-DR)…
Abstract Number: 2268 • ACR Convergence 2022
Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Cecile Yelnik¹, Zeynep Belce Erton², Elodie Drumez³, Dachi Cheildze², Danieli Castro Oliveira de Andrade⁴, Ann E Clarke⁵, Maria G. Tektonidou⁶, Vittorio Pengo⁷, Savino Sciascia⁸, Amaia Ugarte⁹, H Michael Belmont¹⁰, Mª Angeles Aguirre¹¹, Paul fortin¹², maria gerosa¹³, Flavio Victor Signorelli¹⁴, Tatsuya Atsumi¹⁵, Zhouli Zhang¹⁶, Hannah Cohen¹⁷, D. Ware Branch¹⁸, Denis Wahl¹⁹, Laura Andreoli²⁰, Esther Rodriguez Almaraz²¹, Michelle Petri²², Ricard Cervera²³, Yu Zuo²⁴, Bahar Artim-Esen²⁵, Guillermo Pons-Estel²⁶, Rohan Willis²⁷, Maria Laura Bertolaccini²⁸, Robert Roubey²⁹, Doruk Erkan² and on behalf of APS ACTION On Behalf Of APS ACTION², ¹Lille University, Lille, France, ²Hospital for Special Surgery, New York, NY, ³Université de Lille, Lille, France, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ⁶National and Kapodistrian University of Athens, Athens, Greece, ⁷Padova University Hospital, Padova, Italy, ⁸University of Turin, Torino, Italy, ⁹BioCruces Bizkaia Health Research Institute, Barakaldo, Spain, ¹⁰NYU School of Medicine, New York, NY, ¹¹Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, ¹²CHU de Québec, Pavillon CHUL, Québec, Canada, ¹³University of Milan, Milano, Italy, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁵Hokkaido University, Sapporo, Japan, ¹⁶Peking University First Hospital, Beijing, China, ¹⁷University College London, London, United Kingdom, ¹⁸University of Utah, Salt Lake City, UT, ¹⁹Université de Nancy, Nancy, France, ²⁰Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²³Hospital Clínic de Barcelona, Barcelona, Spain, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Istanbul University, Istanbul, Turkey, ²⁶CREAR, Rosario, Argentina, ²⁷University of Texas Medical Branch, Galveston, TX, ²⁸King's College London, London, United Kingdom, ²⁹University of North Carolina, Chapel Hill, NC
Background/Purpose: Long-term anticoagulation is the standard of care for antiphospholipid syndrome (APS) patients with macrovascular thrombosis. However, in daily practice, long-term anticoagulation may not be…
Abstract Number: 0671 • ACR Convergence 2022
Thrombocytopenia and Autoimmune Hemolytic Anemia in Antiphospholipid Antibody-positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Rebecca K.Leaf², Danieli Castro Oliveira de Andrade³, Megan Barber⁴, Maria G. Tektonidou⁵, Vittorio Pengo⁶, Savino Sciascia⁷, Amaia Ugarte⁸, H Michael Belmont⁹, Chary López-Pedrera¹⁰, Paul R Fortin¹¹, maria gerosa¹², Guilherme de Jesús¹³, Tatsuya Atsumi¹⁴, ZHUOLI ZHANG¹⁵, Hannah Cohen¹⁶, D. Ware Branch¹⁷, Denis WAHL¹⁸, Laura Andreoli¹⁹, Esther Rodriguez Almaraz²⁰, Michelle Petri²¹, Ricard Cervera²², Yu (Ray) Zuo²³, Bahar Artim-Esen²⁴, ²⁵, Rohan Willis²⁶, Maria Laura Bertolaccini²⁷, Robert Roubey²⁸, Doruk Erkan¹ and on behalf of APS ACTION On Behalf Of APS ACTION¹, ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital, Boston, MA, ³Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵National and Kapodistrian University of Athens, Athens, Greece, ⁶Padova University Hospital, Padova, Italy, ⁷University of Turin, Torino, Italy, ⁸BioCruces Bizkaia Health Research Institute, Barakaldo, Spain, ⁹NYU School of Medicine, New York, NY, ¹⁰Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ¹²University of Milan, Milano, Italy, ¹³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁴Hokkaido University, Sapporo, Japan, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁷University of Utah, Salt Lake City, UT, ¹⁸University of Lorraine, Nancy, France, ¹⁹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²²Hospital Clinic Barcelona, Barcelona, Spain, ²³University of Michigan, Ann Arbor, MI, ²⁴Istanbul University, Istanbul, Turkey, ²⁵Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ²⁶University of Texas Medical Branch, Galveston, TX, ²⁷King's College London, London, United Kingdom, ²⁸University of North Carolina, Chapel Hill, NC
Background/Purpose: The APS ACTION Registry was created to study the natural course of antiphospholipid syndrome (APS) over 10 years in persistently antiphospholipid antibody (aPL) positive…
Abstract Number: 0687 • ACR Convergence 2022
DNA- and NET-Binding Beta-2 Glycoprotein I in a Large Cohort of Antiphospholipid Antibody-Positive Patients
Katarina Kmetova¹, Srilakshmi Yalavarthi², Claire Hoy², Cyrus Sarosh³, Noah Peters², Tristin Smith², Sherwin Navaz², Yu Zuo² and Jason S Knight⁴, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Temperance, MI, ⁴University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: Beta-2 glycoprotein I (β2GPI) is an abundant plasma protein and a critically important autoantigen in APS. While β2GPI has been reported to have antioxidant,…
Abstract Number: 2269 • ACR Convergence 2022
Anti-NET Antibodies in Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Yu (Ray) Zuo¹, Sherwin Navaz¹, Alex Tsodikov¹, Katarina Kmetova², Claire Hoy¹, Srilakshmi Yalavarthi¹, Danieli Castro Oliveira de Andrade³, Maria G. Tektonidou⁴, Savino Sciascia⁵, Vittorio Pengo⁶, Guillermo Ruiz-Irastorza⁷, H Michael Belmont⁸, maria gerosa⁹, Paul fortin¹⁰, Guilherme de Jesús¹¹, D. Ware Branch¹², Laura Andreoli¹³, Esther Rodriguez Almaraz¹⁴, Michelle Petri¹⁵, Ricard Cervera¹⁶, Rohan Willis¹⁷, Doruk Erkan¹⁸ and Jason S Knight¹⁹, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵University of Turin, Torino, Italy, ⁶Padova University Hospital, Padova, Italy, ⁷Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ⁸NYU School of Medicine, New York, NY, ⁹University of Milan, Milano, Italy, ¹⁰CHU de Québec, Pavillon CHUL, Québec, Canada, ¹¹Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹²University of Utah, Salt Lake City, UT, ¹³Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ¹⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁶Hospital Clínic de Barcelona, Barcelona, Spain, ¹⁷University of Texas Medical Branch, Galveston, TX, ¹⁸Hospital for Special Surgery, New York, NY, ¹⁹University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: The release of neutrophil extracellular traps (NETs) by hyperactive neutrophils plays a role in the thromboinflammatory phenotype of APS. Previous work has demonstrated that…
Abstract Number: 0672 • ACR Convergence 2022
Immune Thrombocytopenia Could Be an Independent Phenotype of Primary Antiphospholipid Syndrome
Yu Shi¹, Jiuliang Zhao² and Xiaofeng Zeng², ¹Chinese Academy of Medical Sciences, Peking Union Medical College, Dongcheng Qu, China, ²Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: Among patients with immune thrombocytopenia (ITP), 10-30% of them were found with positive antiphospholipid antibodies (aPLs) but without typical clinical manifestations of antiphospholipid syndrome…
Abstract Number: 0688 • ACR Convergence 2022
Antibodies of the IgA Isotype Target Neutrophil Extracellular Traps in APS
Sherwin Navaz¹, Lyndsay Kluge¹, Katarina Kmetova², Bruna Jacintho³, Srilakshmi Yalavarthi¹, Claire Hoy¹, Cyrus Sarosh⁴, Noah Peters¹, Tristin Smith¹, Gabriel Figueroa Parra⁵, Jacqueline Madison¹, Kristen Demoruelle⁶, Ali Duarte-Garcia⁵, Jason S Knight⁷ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, São Paulo, Brazil, ⁴University of Michigan, Temperance, MI, ⁵Mayo Clinic, Rochester, MN, ⁶University of Colorado Anschutz Medical Campus, Aurora, CO, ⁷University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: Neutrophil extracellular traps (NETs) are prothrombotic and proinflammatory webs of nuclear DNA, histones, and microbicidal proteins extruded by neutrophils into the extracellular space in…
Abstract Number: 2270 • ACR Convergence 2022
Evidence for Mitochondrial Dysfunction in Blood-derived Endothelial Colony Forming Cells Isolated from Patients with Antiphospholipid Syndrome
Lida Kabir, Robert Maughan, Koralia Paschalaki, Anna Randi, David Carling, Deepa Arachchillage, Justin Mason and Charis Pericleous, Imperial College London, London, United Kingdom
Background/Purpose: The endothelium is a major target of pathogenic antiphospholipid antibodies (aPL) found in patients with antiphospholipid syndrome (APS). It is well established that aPL…
Abstract Number: 0673 • ACR Convergence 2022
Occurrence and Severity of Bleeding in Adults with Immunogenic Thrombocytopenic Purpura with or Without Antiphospholipid Autoantibodies
Izabella Elgardt¹, Or Carmi², Wakar Garra³ and Yair Levy⁴, ¹Sackler Faculty of Medicine, Tel Aviv University, 69978, Israel Department of Internal Medicine E, Meir Medical Center, Kefar Sava, Israel, ²Meir Hospital, Kfar Saba, Israel, ³Sackler Faculty of Medicine, Tel Aviv University, 69978, Israel Department of Internal Medicine E, Meir Medical Center, Kfar Saba, Israel, ⁴Meir Medical Center, Gany Tikva, Israel
Background/Purpose: ITP is an autoimmune disease defined as an isolated platelet count. It may be asymptomatic or accompanied by varying degrees of bleeding. APS is…
Abstract Number: 0689 • ACR Convergence 2022
Type I Interferon Stimulated Genes Identify Different Phenotypes of Antiphospholipid Syndrome Patients
Irene Cecchi¹, Massimo Radin², Alice Barinotti², Silvia Grazietta Foddai², Elena Rubini², Ana Suárez³, Simone Baldovino², Elisa Menegatti², Dario Roccatello², Savino Sciascia¹ and Javier Rodríguez-Carrio⁴, ¹University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³University of Oviedo, Oviedo, Spain, ⁴University of Oviedo,, Oviedo, Spain
Background/Purpose: At present, a limited number of evidencesis available on the specific role of Type I Interferons (IFN) activation in antiphospholipid antibodies (aPL) positive patients,…
Abstract Number: 2271 • ACR Convergence 2022
Circulating Calprotectin: A Potential New Biomarker for “Non-Criteria” Clinical Manifestations of Antiphospholipid Syndrome
Claire Hoy¹, Naveen Kumar S K¹, Sherwin Navaz¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh², Noah Peters¹, Tristin Smith¹, Gary Norman³, Gabriel Figueroa Parra⁴, Johann Gudjonsson¹, J. Michelle Kahlenberg¹, Jacqueline Madison¹, Ali Duarte-Garcia⁴, Jason S Knight⁵ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI, ³INOVA Diagnostics, San Diego, CA, ⁴Mayo Clinic, Rochester, MN, ⁵University of Michigan, Division of Rheumatology, Ann Arbor, MI

Background/Purpose: While thrombosis and pregnancy loss are the best-known features of APS, many patients also exhibit "non-criteria" manifestations such as thrombocytopenia and heart valve damage.…
Abstract Number: 0674 • ACR Convergence 2022
Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies
Vincent Tran, Amy Schmitt and Shanthini Kasturi, Tufts Medical Center, Boston, MA
Background/Purpose: Thrombosis and thrombocytopenia are defining characteristics of antiphospholipid syndrome (APS), but can also be seen in heparin-induced thrombocytopenia (HIT). Hospitalized patients with APS are…
Abstract Number: 0690 • ACR Convergence 2022
The Physiological Ketone Body Beta-Hydroxybutyrate Potently Neutralizes APS-Associated NETosis
Ajay Tambralli¹, Alyssa Harbaugh¹, Christine Rysenga¹, Kaitlyn Sabb¹, Srilakshmi Yalavarthi¹, Claire Hoy¹, Yu (Ray) Zuo¹ and Jason S Knight², ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: Malleable metabolic pathways guide both productive and pathological neutrophil functions, including neutrophil extracellular trap release (NETosis). NETosis plays an important role in APS pathophysiology.…
Abstract Number: 0675 • ACR Convergence 2022
Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort
Jose A Meade-Aguilar¹, Gabriel Figueroa Parra¹, Hannah Langenfeld², Rodrigo Cartin-Ceba¹, Ulrich Specks¹, Cynthia Crowson³ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN
Background/Purpose: Antiphospholipid syndrome (APS) is associated with diffuse alveolar hemorrhage (DAH). However, only case reports and small case series are available in the literature. We…

« Previous Page
1
…
5
6
7
8
9
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].